Ligand Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise
Idag, 14:57
Idag, 14:57
08:57 AM EDT, 05/07/2026 (MT Newswires) -- Ligand Pharmaceuticals (LGND) reported Q1 adjusted earnings of $1.63 per diluted share, up from $1.33 a year earlier.
Revenue for the quarter ended March 31 was $51.7 million, up from $45.3 million a year earlier.
Analysts surveyed by FactSet expected $58.7 million.
The company said it expects full-year 2026 adjusted earnings of approximately $8.50 to $9.50 per diluted share.
Analysts surveyed by FactSet expect $8.99.
The company expects full-year 2026 revenue of $270 million to $310 million.
Analysts polled by FactSet expect $281.9 million.
Idag, 14:57
08:57 AM EDT, 05/07/2026 (MT Newswires) -- Ligand Pharmaceuticals (LGND) reported Q1 adjusted earnings of $1.63 per diluted share, up from $1.33 a year earlier.
Revenue for the quarter ended March 31 was $51.7 million, up from $45.3 million a year earlier.
Analysts surveyed by FactSet expected $58.7 million.
The company said it expects full-year 2026 adjusted earnings of approximately $8.50 to $9.50 per diluted share.
Analysts surveyed by FactSet expect $8.99.
The company expects full-year 2026 revenue of $270 million to $310 million.
Analysts polled by FactSet expect $281.9 million.
Svensk ekonomi
Analys
Lyxsektorn
Riksdagsvalet 2026
Svensk ekonomi
Analys
Lyxsektorn
Riksdagsvalet 2026
1 DAG %
Senast
OMX Stockholm 30
−1,21%
(16:56)
OMX Stockholm 30
1 DAG %
Senast
3 121,05